semaglutide goodyear & tirzepatide are transforming diabetes & obesity management. These GLP-1 receptor agonists offer benefits from glycemic control to weight loss and cardiovascular risk reduction, emphasizing their broad impact. Read more from Who can prescribe semaglutide for

Both reached Canadian pharmacies in the type 2 diabetes indication (Ozempic-equivalent) in May 2026, followed by a 2.4 mg weight-management generic in late 2026 or early 2027, with generic cash prices expected to ease further as more manufacturers launch and several provinces review the generic for public-plan coverage [3]

[DOI] [PubMed] [Google Scholar] 42.Njuma O.J., Davis I., Ndontsa E.N., Krewall J.R., Liu A., Goodwin D.C

The FDA has now sent more warning letters to pharmaceutical and telehealth firms to remove misleading advertisements in the past 6 months than over the entire preceding decade

Now, "my body finally feels like I'm functioning properly